Article excerpt
Funding will support clinical trials, advancement toward FDA approval, and planned commercial deployment of the company's AI-enabled endovascular robotic platform and software suite SAN FRANCISCO, Nov. 16, 2026 /PRNewswire/ -- Remedy Robotics, Inc. ("Remedy"), a leading healthcare and physical AI company developing robotic systems for cardiovascular care and endovascular intervention, today announced it has raised $62 million in Series B funding to accelerate its mission of delivering flawless,
Extracted from this sentence
DCVC led the Series B, with participation from new investors including UC Investments (the University of California's investment office), Skip Capital, and Hostplus (one of Australia's largest pension funds).